Breakthrough Victoria has invested in xCystence Bio, a Victorian biotechnology company developing new treatments for polycystic kidney disease (PKD) - a serious inherited condition and one of the leading genetic causes of kidney failure globally.
The investment supports the translation of world-class Victorian research into potential new medicines that could significantly improve quality of life for people living with PKD.
The Company | xCystence Bio |
The University Partner | Monash University |
The challenge
PKD affects an estimated 12 million people worldwide. The condition causes fluid-filled cysts to grow in the kidneys over time, often leading to chronic pain, reduced kidney function, dialysis or kidney transplantation.
While existing treatments can help manage symptoms, there are currently limited options that directly target the underlying drivers of the disease.
The company
xCystence Bio is a spinout from Monash University and supported by BioCurate. The company is developing a novel therapeutic approach aimed at slowing or stopping disease progression, rather than simply managing its effects.
Its work builds on years of world-class Victorian research, with a focus on translating scientific discovery into medicines that could deliver meaningful benefits for patients.
The investment
Breakthrough Victoria’s investment is made through its University Innovation Platform (UIP), delivered in partnership with Monash University and Monash Ventures, other investors include BioCurate and UniSeed.
The investment reflects Breakthrough Victoria’s role as a patient, long-term investor, backing early-stage companies with the potential to deliver both strong commercial returns and significant public benefit.
Why it matters
The global market for PKD treatments is estimated to be worth around US$2.5 billion per year and is expected to grow steadily as populations age and demand for improved therapies increases.
By supporting companies like xCystence Bio, Breakthrough Victoria is helping ensure that breakthrough medical discoveries are developed, scaled and commercialised in Victoria - creating the foundations for future industries, skilled jobs and better health outcomes.
If successful, xCystence Bio’s work could reduce the burden on patients and health systems worldwide, while positioning Victoria at the forefront of a growing global market for next-generation kidney disease treatments.